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Introduction: Klebsiella pneumoniae carbapenemase (KPC) belongs to the Group-A β- 
lactamases that incorporate serine at their active site and hydrolyze various penicillins, 
cephalosporins, and carbapenems. Metallo-beta-lactamases (MBLs) are group-B enzymes 
that contain one or two essential zinc ions in the active sites and hydrolyze almost all 
clinically available β-lactam antibiotics. Klebsiella pneumoniae remains the pathogen with 
the most antimicrobial resistance to KPC and MBLs.
Methods: This research investigated the blaKPC, and MBL genes, namely, blaIMP, 
blaVIM, and blaNDM-1 and their phenotypic resistance to K. pneumoniae isolated from 
urinary tract infections (UTI) in Bangladesh. Isolated UTI K. pneumoniae were identified by 
API-20E and 16s rDNA gene analysis. Their phenotypic antimicrobial resistance was 
examined by the Kirby-Bauer disc diffusion method, followed by minimal inhibitory con-
centration (MIC) determination. blaKPC, blaIMP, blaNDM-1, and blaVIM genes were 
evaluated by polymerase chain reactions (PCR) and confirmed by sequencing.
Results: Fifty-eight K. pneumoniae were identified from 142 acute UTI cases. Their 
phenotypic resistance to amoxycillin-clavulanic acid, cephalexin, cefuroxime, ceftriaxone, 
and imipenem were 98.3%, 100%, 96.5%, 91.4%, 75.1%, respectively. Over half (31/58) of 
the isolates contained either blaKPC or one of the MBL genes. Individual prevalence of 
blaKPC, blaIMP, blaNDM-1, and blaVIM were 15.5% (9), 10.3% (6), 22.4% (13), and 19% 
(11), respectively. Of these, eight isolates (25.8%, 8/31) were found to have two genes in four 
different combinations. The co-existence of the ESBL genes generated more resistance than 
each one individually. Some isolates appeared phenotypically susceptible to imipenem in the 
presence of blaKPC, blaIMP, blaVIM, and blaNDM-1 genes, singly or in combination.
Conclusion: The discrepancy of genotype and phenotype resistance has significant con-
sequences for clinical bacteriology, precision in diagnosis, the prudent selection of antimi-
crobials, and rational prescribing. Heterogeneous phenotypes of antimicrobial susceptibility 
testing should be taken seriously to avoid inappropriate diagnostic and therapeutic decisions.
Keywords: Klebsiella pneumoniae, blaKPC, blaIMP, blaNDM-1, blaVIM, co-resistance, 
heteroresistance, urinary tract infections, Bangladesh
Introduction
Currently, β-lactams are the most extensively used antibiotics, which include 
natural and synthetic penicillins and their derivatives such as cephalosporins, 
cephamycins, monobactams, and carbapenems.1 Bacterial β-lactamase enzymes 
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that hydrolyze the β-lactam ring inactivate the drugs, 
thereby conferring resistance. Biochemically β-lactamase 
enzymes are classified into two broad groups. The first 
group of enzymes incorporate serine at their active site and 
hydrolyze the amide bond in the lactam ring of antibiotics 
to render it inactive.2 The second group is metallo-β- 
lactamases (MBLs) that contain one or two essential zinc 
ions in the active sites and facilitate a hydrolytic reaction 
to target drugs.3 The widely known Ambler classification 
of β-lactamases divides these enzymes into four molecular 
classes (A, B, C, and D) based upon the amino acid 
sequences and molecular homology between active site 
amino acid motifs.4 Klebsiella pneumoniae carbapenemase 
(KPC) belongs to the Group-A β-lactamases, which hydro-
lyze penicillins, cephalosporins, and carbapenems,5,6 and 
is inhibited partially by class A inhibitors such as clavu-
lanate or tazobactam.7 Group C comprises cephalospori-
nases, including the CMY-family AmpC,8,9 and Group 
D are oxacillinase, consisting of OXA-48, OXA-23, and 
similar enzymes.10,11 Unlike the serine-active proteins, 
MBLs exhibit wide-spectrum hydrolysis in all beta- 
lactams except aztreonam, also clavulanate or tazobactam 
cannot repress MBLs.12 Among nine types of reported 
MBLs, blaIMP, blaNDM, and blaVIM are the most pre-
valent genes worldwide, including in Africa, Asia, Europe, 
and the Americas.13 blaIMP-1 emerged and spread during 
the early 1990s in Japan then was found in other 
countries.14 The blaVIM (Verona Integron-encoded 
Metallo β-lactamase) gene was first found in Europe and 
then emerged in other countries. However, blaNDM- 
producing bacteria were first isolated from a Swedish resi-
dent who contracted a urinary tract infection caused by 
carbapenem-resistant K. pneumoniae while he was in New 
Delhi in late 2007.15 Subsequently, the blaNDM gene 
emerged in Pakistan, the Indian subcontinent and the 
United Kingdom.16,17 Multiple resistance genes in the 
same bacterial isolate accumulate some compound pheno-
type known as co-resistance, which was reported among 
ESBLs with an increased opportunity of transmission.18
Gram-negative bacteria, particularly carbapenem- 
resistant Enterobacteriaceae (CRE), currently pose 
a severe global human health threat.19,20 As such, the 
World Health Organization (WHO) identified and priori-
tized CRE as one of the most critical antibiotic-resistant 
bacteria (WHO priority list 2017). Antibiotic resistance in 
CRE is, therefore, a vital area for clinical and public health 
research.21 Most Enterobacteriaceae are healthy flora; how-
ever, some become pathogens, causing a diversified severe 
infection, including systemic bacteremia, community- 
acquired infections, healthcare-associated infections 
(HAIs), and both complicated and uncomplicated urinary 
tract infections (UTIs).22,23 Klebsiella pneumoniae remains 
the leading pathogen producing carbapenemase24 and MBL 
enzymes17,25 and has been reported to show co-resistance 
through containing multiple ESBL genes simultaneously.26 
Some antibiotic resistance genes (ARGs) accumulate multi-
ple random mutations in their gene sequences over time and 
become dysfunctional resistance genes (resistance pseudo-
genes) that fail to exhibit expected resistance phenotypes.27 
The pseudo-ARGs are often considered to comprise non-
functional junk DNA that remains stable in the bacterial 
genome or plasmid.28 They become attenuated or impaired 
in their ability to produce functional β-lactamases, leading 
to phenotype-genotype discrepancies.
The present study investigated the presence of serine 
β-lactamase gene, KPC, and MBL genes, such as blaIMP, 
blaVIM, and blaNDM-1 in Klebsiella pneumoniae isolates 
from UTI patients in Dhaka, Bangladesh. The study also 
analyzed the AMR genotypes and phenotypes of the UTI 
isolates among the four ESBL genes and different β-lactam 
antibiotics.
Materials and Methods
Study Design and Specimen Collection
A cross-sectional study was conducted between 
April 2017 and March 2018 among patients showing clin-
ical signs of a UTI who attended outpatient Departments at 
Gonosastha Medical College Hospital, and Enam Medical 
College Hospital in Savar, Dhaka, Bangladesh. Only 
patients with no history of antibiotic treatment in the 
previous 15 days were invited to participate in the study. 
Patients with a known record of immunocompromised 
diseases, including cancer, organ transplant, HIV/AIDS, 
and renal disorders were also excluded from the study. 
Informed written consent was obtained from each study 
participant prior to collecting their demographic data and 
urine specimens. For participants who were minors, con-
sent was obtained from their parents or legal guardians. 
The patients’ main presenting clinical signs and symptoms 
were recorded using a structured questionnaire. All 142 
patients met the study criteria for microbiological investi-
gation. The standard clean-catch midstream urine sam-
pling procedure was explained to the participants, 
including the importance of avoiding contamination with 
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commensal bacteria,29 then the samples were collected and 
immediately transferred to the laboratory for analysis.
Bacterial Isolation and Identification
Urine samples collected in sterile glass tubes were inocu-
lated on differential culture media, cysteine-, lactose-, and 
electrolyte-deficient (CLED) agar (Lyophilchem, Italy) 
and MacConkey agar. The specimens were plated within 
two hours after collection to avoid false-positive results. 
Using CLED agar medium inhibits the swarming growth 
of Proteus species and other gram-negative bacilli in favor 
of gram-positive cocci if present in the specimen. Urine 
cultures were incubated overnight at 35ºC–37ºC in ambi-
ent air. Quantitative urine cultures were carried out, and 
colony counts of 102 or 103 CFU/mL were considered to 
define a probable UTI infection.30 Colony counts of less 
than 102 CFU/mL were assumed as potentially contami-
nated. The isolates were sub-cultured on nutrient agar 
(Oxoid, UK), and their identification was initially per-
formed by Gram’s staining and biochemical tests, includ-
ing the oxidase test, Kligler iron agar (KIA), Indole test, 
citrate utilization, urease test, and motility test. 
Identification was confirmed by a rapid biochemical-test 
kit (API 20E, BioMe´rieux, Durham, NC) consisting of 
a set of chromogenic panels, carbohydrate batteries, and 
enzymatic substrates.31 The bacterial identity was vali-
dated further by the amplification and sequencing of the 
16S rDNA gene.32 The isolates were preserved in 30% 
glycerol at - 20ºC in Trypticase Soy Broth (TSB) until 
further analysis. This study included only the exclusive 
Klebsiella pneumoniae isolates from UTI patients of all 
age groups and both sexes. Samples infected with co- 
pathogens were excluded from the analyses.
Antimicrobial Susceptibility Testing
The phenotypic antimicrobial susceptibilities of the iso-
lates were tested by the disc diffusion method (Kirby– 
Bauer) on Mueller–Hinton agar (Oxoid, Basingstoke, 
UK) plates according to the Clinical and Laboratory 
Standards Institute (CLSI) guidelines.33 Briefly, a 4-hour 
bacterial suspension in Mueller–Hinton broth was adjusted 
to a density of McFarland 0.5 equivalent and then evenly 
streaked on MHA plates to ensure consistent growth. 
Antibiotic discs were placed on the bacterial lawn and 
incubated at 37ºC overnight to determine the sensitivity 
pattern. Sensitive bacteria developed a clear zone around 
each disc, and zone diameter was measured and evaluated. 
Escherichia coli ATCC25922 was used as the susceptible- 
control reference strain for disc diffusion testing. 
Antibiotic discs were procured from Oxoid limited 
(Basingstoke, UK). The β-lactam antibiotics tested were 
as follows: Amoxycillin+Clavulinic acid (30 µg), 
Cephalexin (30 µg), Cefuroxime Sodium (30 µg), 
Ceftriaxone (30 µg), Cefepime (30 µg), and Imipenem 
(10 µg). Outside the β-lactam group, two commonly pre-
scribed antibiotics for UTI, namely, trimethoprim/sulfa-
methoxazole (25 µg) and ciprofloxacin (5 µg) were also 
included for susceptibility assessment.
Minimum Inhibitory Concentration (MIC) 
Determination
Resistant isolates from the Kirby-Bauer test were further 
analysed to determine the lowest concentration of antibio-
tics required to inhibit their visible growth (minimal inhi-
bitory concentration, MIC). The agar microdilution 
method was employed primarily to check the MIC.13,34 
Etest was carried out on imipenem only in parallel to 
validate the former MIC results.35 In the procedure, com-
mercial Etest strips carrying concentration gradient (from 
0.016 to 256 μg/mL) of imipenem was examined (BioMe 
´rieux, Durham, NC) according to the manufacturer’s 
instructions. MH agar plates were inoculated with standar-
dized (0.5 McFarland Standard) saline suspension of each 
isolate prepared from overnight cultures on MH agar 
plates. Etest strips were carefully layered on each inocu-
lated plate, and plates were incubated at 35°C for 18 hours. 
Results were interpreted for K. pneumoniae, according to 
the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST, Version 7.1 2017). The clinical break-
points for imipenem resistance were considered when the 
MIC value was > 8 μg/mL.36
PCR of blaKPC, blaIMP, blaNDM-1, and 
blaVIM Genes
All the isolates were subjected to a polymerase chain 
reaction (PCR) test for genotypic confirmation of serine β- 
lactamase gene, KPC, and MBL genes, including blaIMP, 
blaVIM, and blaNDM-1. The total DNA of all the bacter-
ial isolates was extracted by the boiling method from 
bacteria grown on nutrient agar media.15 Specific primer 
sets for the respective genes were selected based on pre-
vious literature37,38 and synthesized from Integrated DNA 
Technology (IDT, Singapore). For each PCR reaction, 
prepared bacterial DNA 2.0 µL was added to a 12 µL 
2X PCR pre-mixture (GeneON, Germany) and five pmol 
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of each primer (1 µL), and the remaining deionized water 
to make a final volume of 24 µL. Reactions underwent an 
initial denaturation at 95°C for 10 min followed by 32 
cycles of amplification (Applied Biosystems 2720 Thermal 
Cycler, Singapore), consisting of denaturation 30s at 94 ° 
C, annealing 30s at 52–56 °C depending on primer sets, 
extension 1 min at 72°C, and a final 7 min extension at 72° 
C. Amplicons were visualized under UV light after elec-
trophoresis through 1.2% agarose gel at 100 volts for 30 
minutes, followed by staining with ethidium bromide. The 
standard molecular weight marker was run in parallel to 
measure specific amplicon sizes (GeneRuler, 
ThermoFisher Scientific, MA).
Statistical Analysis
Data were verified, entered, and subsequently analyzed 
using IBM SPSS statistics data editor (version 21). 
Missing data were omitted from the bivariate analysis. 
Descriptive and inferential statistical procedures were 
used to describe the UTI Klebsiella pneumoniae and 
their carriage of ESBL genes and phenotypic attributes. 
Pearson’s chi-square test was used to test any association 
between categorical data, and Yate’s correction for con-
tinuity was applied where required. The correlation coeffi-
cient was calculated to check the strength of the 
association. A two-tailed p-value was calculated to mea-
sure statistical significance.
Ethics Statement
This study was approved by the Ethics and Research 
Review Committee of the Jahangirnagar University (JU) 
Faculty of Biological Sciences [No. BBEC, JU/M 2017 
3(4) dated 15.03.2017]. This research was carried out from 
an undertaken capstone project of the University. 
However, JU did not have a full-fledged hospital, from 
where required biospecimens could be obtained. 
Therefore, we made research collaborations with nearby 
private hospitals, namely, Gonosastha Medical College 
Hospital and Enam Medical College Hospital. Both the 
private hospitals had accepted the Ethical permission that 
was taken from JU. Therefore, we completed this work 
under a common ethical permission. All the study proto-
cols complied with the Declaration of Helsinki for recruit-
ing human subjects for medical research. Written informed 
consent was obtained from adult study patients for collect-
ing the urine samples. Separate written informed consent 
was taken from parents or legal guardians for patients 
under 18 years of ages. A respective sample identification 
code was assigned to each sample collected. The personal 
identities and other information on the participants were 
strictly anonymised to protect their privacy.
Results
Study Participants and Klebsiella 
pneumoniae Prevalence
During the one year study period, urine samples of 142 
patients attending two hospitals in Dhaka city with acute 
urinary tract infection (UTI) were examined, and 58 
(40.8%) Klebsiella pneumoniae isolates were identified. 
All the urine samples appeared culture-positive with at 
least one UTI pathogen. Most of the participants were 
consistently symptomatic. Most of them reported 
a continuous urge to urinate, a burning sensation during 
urination, and an incomplete or empty feeling in their 
bladder. The mean age (±Standard Deviation) of the 
study patients with Klebsiella pneumoniae infection was 
35.7±15.6 years. The age range was from 4 to 76 years. 
Further subclassification showed that the 20 to 39 years 
age-group accounted for 44.8% of infections. Incidence 
was higher among females, 72.4% (n=42) compared to 
27.6% (n=16) in males. However, further analysis shows 
no significant association between K. pneumoniae growth 
from the urine cultures with age-group [χ2(2, N=142) 
=1.536, p=0.464] and sex [χ2(1, N=142) =0.714, 
p=0.398]. The details of the comparison are shown in 
Figure 1.
Phenotypic Antimicrobial Susceptibility 
and Minimum Inhibitory Concentration
In vitro antimicrobial potency of the most frequently pre-
scribed orally administered β-lactam antibiotics was tested 
based on the disc diffusion method against the 58 UTI 
Klebsiella pneumoniae. Semi-synthetic penicillin, amoxycil-
lin-clavulanic acid showed very weak potency against the 
test pathogens, where 98.3% of isolates were resistant. First- 
generation cephalosporins such as cephalexin were among 
the least potent antimicrobial, with 100% resistance. 
The second-generation cephalosporin, cefuroxime sodium, 
was also ineffective, with 96.6% of the pathogens evaluated 
being resistant. The extended-spectrum third generation and 
the fourth generation cephalosporins, such as ceftriaxone 
and cefepime, showed a negligible functional spectrum of 
activities against only 8.6% of test pathogens: the remaining 
91.4% were resistant. In contrast, a carbapenem antibiotic, 
imipenem, was moderately active against the uropathogens, 
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with 25.9% (15/58) of isolates appearing susceptible. Both 
ciprofloxacin and trimethoprim/sulfamethoxazole showed 
moderate activity with susceptibility outputs of 38% (22/ 
58) and 19% (11/58), respectively. The MIC of imipenem 
for resistance varied from >8 µg/mL to >256 µg/mL. Thus, 
the MIC results correlated with the disc-diffusion results. 
The susceptible control, ATCC strain Bacillus cereus, and 
imipenem susceptible (by disc diffusion) isolates exhibited 
a MIC <2 µg/mL. MIC assessment by commercial Etest 
strips also matched the agar diffusion test findings, therefore 
the tests validated each other.
Genotypic-Phenotypic Agreement of 
blaKPC, blaIMP, blaNDM-1, and blaVIM
Serine β-lactamase gene blaKPC was detected in 9 (15.5%) 
UTI K. pneumoniae by PCR. The MBL genes, blaIMP, 
blaNDM, and blaVIM, were detected in 6 (10.3%), 13 
(22.4%), and 11 (19%) isolates, respectively. None of the 
isolates containing the blaKPC gene was susceptible to 
Amoxycillin-clavulanic acid, cephalexin, cefuroxime 
sodium, and ceftriaxone, one isolate (11.1%) showed suscep-
tible to cefepime and three isolates (33.3%) to imipenem. 
About 75% and 90% of the isolates without harboring the 
blaKPC gene exhibited resistance to imipenem and ceftriax-
one, respectively. The results were similar to other β-lactam 
antibiotics; however, the degree of resistance was somewhat 
lower among the KPC-naïve bacteria. Cephalexin (30µg), 
a first-generation cephalosporin, was found to be ineffective 
on isolates with or without carrying the blaKPC gene (Figure 
2A). Among the blaIMP-positive isolates (n=6), 16.7% sen-
sitivity was observed to Amoxycillin-clavulanic acid, cefur-
oxime, ceftriaxone, and cefepime. Furthermore, imipenem 
was found susceptible to 33.3% of IMP-positive and 25% of 
IMP-negative isolates. Therefore, the presence or absence of 
the blaIMP gene did not greatly affect phenotypic suscept-
ibility to imipenem. Moreover, some lower susceptibility was 
observed among IMP-naive pathogens to antibiotics of the 
tested β-lactam panel (Figure 2B). Among the blaVIM- 
positive isolates (n=11), none was susceptible to either of 
the tested Amoxyclav and cephalosporins. blaVIM-negative 
isolates showed a comparative higher sensitivity, and imipe-
nem remained the most active drug, showing potency to 
18.8% of VIM-positive and 27.7% of VIM-negative isolates 
(Pearson chi-square, p=0.71). In all cases, cephalexin was 
100% ineffective on all isolates regardless of the presence of 
the blaVIM gene (Figure 2C). Among 13 New Delhi Metallo 
β-lactamase-containing isolates, none was susceptible to 
Amoxyclav or either of cephalosporins examined, while the 
blaNDM-negative isolates showed some higher degree of 
susceptibility. Imipenem remained almost equally sensitive, 
23% to NDM-positive, and 27% to NDM-negative isolates 
(Pearson chi-square, p=1.0), respectively. Consistently, 
cephalexin remained ineffective regardless of whether the 
isolates carried the blaNDM-1 gene or not (Figure 2D). 
The overall presence of the blaKPC gene or MBL genes 
influenced reduced susceptibility among the UTI 
Figure 1 Gender and age distribution of K. pneumonia-positive and -negative UTI patients. Frequency distribution of urine culture with K. pneumonia positive (+ve) and 
negative (-ve) according to sex (male and female) and age group (1–20 YO, 21–40 YO and more than 40 YO) (n=142, Years Old = YO).
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K pneumoniae isolates. However, there was no statistically 
significant association between the antimicrobial susceptibil-
ity and the presence of the ESBL genes. The relatively small 
sample size in this study may have affected the statistical 
association observed. The difference between phenotypic 
susceptibility in the presence of the blaKPC and MBL 
genes was noticeable.
Association Between Phenotypic 
Antimicrobial Susceptibility with Age and 
Sex
Fisher’s Exact test was used to assess the association 
between the phenotypic antimicrobial susceptibility with 
age and sex because the expected frequency assumption 
was not sufficient to use the Chi-square test for the major-
ity of antimicrobials. Age and antimicrobial susceptibility 
were reclassified into two groups, and sensitive and inter-
mediate antimicrobial susceptibility were combined into 
one group to be compared with the samples resistant to 
antimicrobials. It was found that none of the phenotypic 
antimicrobial susceptibility tested on the urine samples 
with the growth of K. pneumonia showed any significant 
relationship with either age or sex, with p-values ranging 
from 0.053 to 1.000. Details of the test are shown in Table 
1, except for cephalexin, where the analysis could not be 
performed because all samples were resistant towards it.
Association Between Genotypic blaKPC, 
blaIMP, blaNDM-1, and blaVIM with Age 
and Sex
As in 2.4, Fisher’s Exact test was used to assess the 
association between genotypic blaKPC, blaIMP, 
blaNDM-1, and blaVIM with age and sex except for 
blaVIM where the Chi-square test was used to compare 
between different age groups. Similarly, no significant 
results were found, with p-values ranging between 0.097 
and 1.000, as shown in Table 2.
Co-Resistance Phenotypes of blaKPC, 
blaIMP, blaNDM-1, and blaVIM
A total of 31 isolates among 58 K. pneumoniae were found 
to carry at least one of the four ESBL genes. Most of the 
isolates carried a single gene, although some carried 
Figure 2 Impact of Extended Spectrum β-lactamase (ESBL) genes on the phenotypic susceptibilities of β-lactam antibiotics. The comparative susceptibilities of the ESBL- 
positive and -negative isolates were evaluated against selected b-lactam antibiotics, namely Amoxycillin+Clavulinic acid (AMC 30 µg), Cefepime (FEP 30 µg), Cefuroxime 
Sodium (CXM 30 µg), Cephalexin (CL 30 µg), Ceftriaxone (CRO 30 µg), Imipenem (IMP 10 µg). (A). The Y-axis values of black bars indicate the percentage of ESBL gene- 
carrying isolates showing as susceptible against respective antibiotics shown on the X-axis. Similarly, the white bars illustrate the percentages of susceptible isolates that do 
not carry the respective ESBL genes. Susceptibilities of (A) blaKPC-positive (n=9) and -negative (n=49), (B) blaIMP-positive (n=6) and -negative (n=52), (C) blaVIM-positive 
(n=11) and -negative (n=47), and (D) blaNDM1-positive (n=13) and -negative (n=45), isolates are shown separately.
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multiple genes simultaneously. Co-existing ESBL genes 
were found in four combinations: blaVIM +blaKPC, 
blaVIM +blaIMP, blaVIM +blaNDM-1, and blaNDM-1 
+blaIMP. bla-VIM had the highest combination of co- 
existence with KPC, IMP, and NDM. From 11 isolates 
carrying blaVIM-gene, four were mutually exclusive; 
five had a concurrence with NDM, one with KPC and 
one with IMP. Another co-existence was found in one 
isolate between IMP and NDM (Figure 3). Thus, there 
were eight isolates (25.8%, 8/31) containing any two of 
the ESBL genes. The remaining 23 (74.2%) isolates hosted 
ESBL genes independently: eight blaKPC, four blaVIM, 
seven blaNDM-1, and four blaIMP (Figure 3). The similar 
phenotypic susceptibility pattern of the isolates carrying an 
independent- versus co-existing ESBL genes were exam-
ined. Of the eight isolates bearing the blaKPC gene exclu-
sively, two were phenotypic susceptible to imipenem, and 
one was susceptible to imipenem plus cefepime. Similarly, 
independent blaIMP bearing three isolates were sensitive 
to different cephalosporins plus imipenem. Only one 
blaNDM-1 carrying one isolate showed sensitivity to imi-
penem, and the remaining six conferred resistance to all 
tested β-lactam antibiotics. However, only blaVIM con-
taining four isolates was found to confer complete resis-
tance (Table 3). In contrast, the co-existence of the KPC 
+VIM, IMP+VIM, NDM-1+IMP genes gave the isolates 
absolute resistance to the antibiotics tested. Finally, despite 
co-harboring blaVIM+blaNDM-1, two isolates appeared 
sensitive to imipenem; however, the other three were com-
pletely resistant to all the antibiotics (Table 3).
Discussion
This study identified Klebsiella pneumoniae as a prevalent 
etiology of UTI in Bangladesh, as stated earlier.39 More 
than half of the K. pneumoniae isolates were found to 
carry at least one MBL or blaKPC gene. These findings 
Table 1 Association Between Phenotypic Antimicrobial Susceptibility of Urine K. Pneumoniae with Age and Sex (Fisher’s Exact Test, 
n=58)
Antimicrobials Age Groups 
Frequency (%)
p-value Sex 
Frequency (%)
p-value
≤ 30 YO 
(n=28)
> 30 YO 
(n=30)
Male 
(n=16)
Female 
(n=42)
Cefuroxime
Sensitive 0 (0) 2 (6.7) 0.492 1 (6.3) 1 (2.4) 0.479
Resistant 28 (100) 28 (93.3) 15 (93.8) 41 (97.6)
Trimethoprim/sulfamethoxazole
Sensitive 6 (21.4) 5 (16.7) 0.644* 6 (37.5) 5 (11.9) 0.055
Resistant 22 (78.6) 25 (83.3) 10 (62.5) 37 (88.1)
Ceftriaxone
Sensitive 3 (10.7) 2 (6.7) 0.665 2 (12.5) 3 (7.1) 0.609
Resistant 25 (89.3) 28 (93.3) 14 (87.5) 39 (92.9)
Amoxycillin-Clavulanic acid
Sensitive 0 (0) 1 (3.3) 1.000 0 (0) 1 (2.4) 1.000
Resistant 28 (100) 29 (96.7) 16 (100) 41 (97.6)
Cefepime
Sensitive 0 (0) 5 (16.7) 0.053 1 (6.3) 4 (9.5) 1.000
Resistant 28 (100) 25 (83.3) 15 (93.8) 38 (90.5)
Ciprofloxacin
Sensitive 9 (32.1) 13 (43.3) 0.380* 7 (43.8) 15 (35.7) 0.573*
Resistant 19 (67.9) 17 (56.7) 9 (56.3) 27 (64.3)
Imipenem
Sensitive 6 (21.4) 9 (30.0) 0.456* 6 (37.5) 9 (21.4) 0.314
Resistant 22 (78.6) 21 (70.0) 10 (62.5) 33 (78.6)
Note: *Chi-square test.
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highlighted that the Indian subcontinent countries, includ-
ing Bangladesh, are a high endemic region for MBL genes 
among K. pneumoniae and other Enterobacteriaceae.16,40 
As a consequence, the evolution of blaKPC- and MBLs- 
based resistance has been disseminated worldwide in most 
Gram-negative bacteria.24,41 Additional research studies 
are needed to develop a deeper understanding of MBL 
prevalence in other UTI pathogens besides 
K. pneumoniae in Bangladesh. As anticipated, single 
occurrences of the blaKPC, blaIMP, blaVIM, and 
blaNDM-1 genes are associated with a reduced suscept-
ibility to all the β-lactam antibiotics tested regardless of 
gender and age variation. These findings are supported by 
many earlier studies.12,13
Further, a co-existence of the blaKPC and MBL genes 
shows more reduced susceptibility to β-lactam antibiotics. 
This co-resistance phenomenon enables bacteria to accumu-
late several genes simultaneously to emerge as high-risk 
UTI clones. Multiple studies have found that the co- 
existence of several genes, notably blaKPC and MBLs, 
into the same bacteria affects decreased sensitivity to dif-
ferent antimicrobials.42,43 Historically, uncomplicated UTIs 
have been treated with empirical antibiotics, including the 
cephalosporins, TMP-SMX, and the fluoroquinolones. This 
widespread use may have led to bacteria acquiring 
increased co-resistance over time. In Bangladesh, UTI is 
a frequent disorder at the community level where many 
patients do not visit medical doctors because of social 
stigma about issues related to genito-urinary conditions. 
Therefore, the more common antibiotics are used, which 
also can lead to resistance. A lack of education, ignorance, 
and lack of money to buy a full course of an appropriate 
drug are other factors that can promote high ARG transmis-
sion among UTI pathogens in the country.
On the other hand, a significant portion of isolates not 
carrying those ESBL genes also showed phenotypic resis-
tance to the same sets of β-lactam antibiotics. The incon-
sistency of the genotype-phenotype association could be 
explained by other resistance genes or factors that have not 
been investigated in this study.44 Varieties of ESBLs genes 
out of KPC or MBL lineage may have contributed to the 
different phenotypic resistance phenomena.45,46
Uncommonly, this study identified that some 
K. pneumoniae isolates appeared phenotypic susceptible, 
particularly to imipenem, in the presence of blaKPC or either 
of the three MBL genes. Two independent experiments gen-
erated the replicated imipenem-sensitive phenotypes of the 
isolates carrying blaKPC or MBL genes. This indicates that 
the acquisition of either of the blaKPC, blaIMP, blaVIM or 
the blaNDM-1 gene is not enough to provide carbapenem- 
resistance. These findings differed from many other reports 
stating MBL genes confer resistance to carbapenem-group 
antibiotics.5,16,17,47 The disparity of ARGs to phenotypic 
attestation has identified the limitation of molecular assays 
Table 2 Association Between Genotypic blaKPC, blaIMP, blaNDM-1, and blaVIM of Urine K. Pneumoniae with Age and Sex (Fisher’s 
Exact Test, n=58)
Age Groups 
Frequency (%)
p-value Sex 
Frequency (%)
p-value
≤ 30 YO 
(n=28)
> 30 YO 
(n=30)
Male 
(n=16)
Female 
(n=42)
blaKPC
Positive 5 (17.9) 5 (16.7) 1.000 2 (12.5) 8 (19.0) 0.710
Negative 23 (82.1) 25 (83.3) 14 (87.5) 34 (81.0)
blaIMP
Positive 5 (17.9) 1 (3.3) 0.097 0 (0) 6 (14.3) 0.173
Negative 23 (82.1) 29 (96.7) 16 (100) 36 (85.7)
blaNDM-1*
Positive 2 (11.8) 6 (27.3) 0.426 2 (28.6) 6 (18.8) 0.617
Negative 15 (88.2) 16 (72.7) 5 (71.4) 26 (81.3)
blaVIM*
Positive 5 (21.7) 6 (24.0) 0.852** 2 (22.2) 9 (23.1) 1.000
Negative 18 (78.3) 19 (76.0) 7 (77.8) 30 (76.9)
Notes: *With some missing values **Chi-square test.
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for antimicrobial resistance determinants. The findings also 
authenticate the conventional antimicrobial phenotypic test-
ing procedures, notably, disc diffusion, microdilution, and 
Etest as “gold-standard” methods. The explanation for the 
expression-discrepancy of the dysfunctional ESBL resis-
tance genes is not well-understood. It is possible that the 
antibiotic itself may modulate the ARGs into low in vitro 
expression,48 or that the heteroresistance phenomena asso-
ciated with unstable tandem gene amplification, rare muta-
tion, and environmental modulation to the resistant genes 
may explain exhibited different susceptibilities.49–51 
Comprehensive whole-genome sequencing (WGS)-based 
analysis could help to identify accurate genotype to pheno-
type resistance association.
This study diagnosed UTI more commonly in females 
than in males. Anatomical differences are reported to 
affect prevalence variation among the two genders.52 
Reproductively active women in the age group 20–39 
years accounted for the majority of UTI presentations in 
this study.53 However, the detection frequency of 
K. pneumonia in all the age groups was almost equal. 
Overall, all generations of cephalosporin antibiotics 
showed a very weak antibacterial potency against the 
UTI K. pneumoniae tested.53 Higher resistance to these 
antibiotics may be due to their extensive use in treating 
UTI and other diseases.54 With the reduced potency of 
cephalosporins, clinicians have started relying more on 
carbapenems. This study identified imipenem as the best 
effective β-lactam antibiotic to treat UTI, although about 
three-quarters of isolates were resistant to it. A previous 
study conducted in Bangladesh identified about 15% of 
imipenem-resistant gram-negative UTI pathogens,40 indi-
cating an increasing trend of carbapenem resistance in 
uropathogens circulating in the country. Again, the emer-
gence of ESBL or carbapenemase-producing 
K. pneumoniae can be linked with increased carbapenem 
consumption.55 The widely used fluoroquinolone drug, 
ciprofloxacin, remained more effective than any of the β- 
lactam antibiotics tested under this investigation.
This study has several crucial limitations. The risk 
behavior data relating to the study participants were 
self-reported and not evaluated in-depth. This study 
was cross-sectional in design and follow up could not 
be carried out due to resource limitations. The conve-
nience sampling was undertaken in a semi-urban area of 
Bangladesh, where a high degree of social stigma exists 
about urogenital diseases. Notably, women feel shy or 
uncomfortable visiting doctors/diagnostics for genitour-
inary diseases until symptoms become very severe. 
Therefore, the patients in this study were presenting 
with acute symptoms and were diagnosed with 
a higher frequency of positive cases than those in 
other similar reports.23 This study analyzed only a few 
ESBL genes and limited β-lactam antibiotics. Only 
K. pneumoniae were analyzed in the study, despite the 
existence of diverse other UTI pathogens. This study did 
not have ATCC-resistant control for AST measurement. 
We used a P. aeruginosa isolated from a skin wound as 
an internal resistant-control. The isolate was tested pre-
viously resistant against 17 different antibiotics from 7 
groups. The small sample size was also a constraint to 
performing fully powered statistical analyses. However, 
our results were generated from a resource-limited set-
ting and maintained internal validity by repeating inde-
pendent experiments where necessary. The findings have 
shed some light on a significant UTI pathogen, their 
Figure 3 Overlapping Extended Spectrum β-lactamase (ESBL) genes. The Venn- 
diagram shows the mutual prevalence of ESBL genes, such as blaKPC, blaIMP, 
blaVIM, and blaNDM-1 in the uropathogen Klebsiella pneumoniae. Each circle is 
labeled with the respective gene-name, and the number in the bracket indicates the 
total count of isolates positive for the specific gene. Numbers in the non- 
overlapping region show the count of isolates carrying respective single-type ESBL 
genes. Numerates in the overlapping region indicate the isolate number carrying the 
respective genes mutually.
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carriage of ESBL genes, co-resistance, and the genoty-
pic-phenotypic association with antibiotic resistance. 
Further studies may be required to assess the external 
validity of our findings.
Conclusions
K. pneumoniae remains a predominant uropathogen in 
Bangladesh. Imipenem was found the drug of choice among 
tested β-lactam antibiotics, superior to trimethoprim- 
sulfamethoxazole and inferior to ciprofloxacin, to treat 
K. pneumoniae causing UTI. The prominent ESBL genes, 
namely, blaKPC, blaIMP, blaVIM, and blaNDM-1, emerged 
in the UTI isolates. A combination of the ESBL genes exerted 
more reduced phenotypic susceptibility than that of each indi-
vidual gene. The presence of the four ESBL genes, singly or in 
conjunction, do not confer absolute resistance to carbapenem 
antibiotics. The discrepancy of genotype and phenotype resis-
tance has significant consequences for clinical bacteriology, 
precision in diagnosis, the prudent selection of antimicrobials, 
and rational prescribing. It highlights that more understanding 
of antimicrobial resistance is required so that more appropriate 
and thus, more effective treatments can be provided.
Table 3 Phenotypic Antibiotic-Resistance of Bacterial Isolates Carrying Single-Type versus Combined-Types ESBLa Genes
ESBL Gene Isolates Susceptibilities to β-Lactam Antibioticsb
AMC-Clav CL CXM CRO FEP IMP
bla-KPC UJ 15 R R R R R R
UJ 21 R R R R R S
UJ 27, C1 R R R R R R
UJ 38 R R R R S S
UJ 45, C1 R R R R R R
UJ 66, C1 R R R R R R
UJ 94 R R R R R S
UJ 123 R R R R R R
bla-VIM + bla-KPC UJ62 R R R R R R
bla-IMP UJ 34 R R R R R S
UJ 69, C1 R R R R R R
UJ 70 R R R S R R
UJ 95 S R S R S S
bla-VIM + bla-IMP UJ 59 R R R R R R
bla-NDM-1+ bla-IMP UJ 40, C1 R R R R R R
bla-VIM UJ 39 R R R R R R
UJ 75 R R R R R R
UJ 76, C1 R R R R R R
UJ 119 R R R R R R
bla-NDM-1 UJ 20 R R R R R S
UJ 29 R R R R R R
UJ 49 R R R R R R
UJ 73 R R R R R R
UJ 78, C2 R R R R R R
UJ 90 R R R R R R
UJ 92 R R R R R R
bla-VIM + bla-NDM-1 UJ 48 R R R R R R
UJ 87, C1 R R R R R R
UJ 87, C2 R R R R R S
UJ 88 R R R R R R
UJ 105 R R R R R S
Notes: aESBL, extended spectrum β-lactamase; bS, susceptible; R, resistant; AMC-Clav, amoxycillin with clavulanic acid, 30 µg; CL, cephalexin, a first generation 
cephalosporin antibiotic, 30 µg; CXM, cefuroxime sodium, a second generation cephalosporin antibiotic, 30 µg; CRO, ceftriaxone, a third generation cephalosporin 
antibiotic, 30 µg; FEP, cefepime, a fourth generation cephalosporin antibiotic, 30 µg; IMP, imipenem, a carbapenem antibiotic, 10 µg.
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Recommendations
1. Diagnostic or clinical laboratories should consider 
the limitations of molecular methods of identifying 
antimicrobial resistance.
2. Results from adopted molecular techniques should be 
validated further by phenotypic outcomes. Any dis-
cordant results should be repeated by additional test-
ing as per the guidelines of a reference laboratory.
3. Heterogeneous phenotypes of antimicrobial sus-
ceptibility testing should be taken seriously to 
avoid imprudent therapeutic decisions.
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